Denosumab in erosive hand OA. 12-weekly dosing, primary end-point at 24 weeks. @RheumNow #ACR22 #LateBreaking

Peresolimab PD-1 agonist in RA Phase 2 RCT Primary endpoint met w/ > improvement DAS28CRP Wk12 Also greater improvement of CDAI in both treated grps TEAEs PBO 37% PER 300mg 40% PER 700mg 35%, 1 serious AE in PER 700mg https://t.co/QtclWIWAw9 Abs#L03 #ACR22 @Rheumnow https://t.co/bLHP4JuNjt

• A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis - ACR Meeti…

Wipfler et al. Characteristics refractory RA. Associations at baseline (A) and follow-up (B) @RheumNow #ACR22 Abstr#1952 https://t.co/4PJtrDp3Ba https://t.co/x1NCq07Y1h

• Burden of Disease in Refractory Rheumatoid Arthritis - ACR Meeting Abstracts

Rossato et al. Women in highest tertile ultra-processed food intake 50% more likely to develop SLE than those in lowest tertile. Exacerbated by high BMI. @RheumNow #ACR22 Abstr#1634 https://t.co/T4Bx59VJPX https://t.co/oWaj9QbzgY

• Association of Ultra-processed Food Intake with Risk of Systemic Lupus Erythema…

Important late breaker re:barriers to MTX post Roe decision 6% of respondents who tried to fill MTX had barriers to access; most commonly related to pharmacies/pharmacists This number should be 0%!! #ACR22 abstr#L09 @RheumNow https://t.co/dgZkJLlL25

Pooled data from AURORA 1 and 2 show that Voclosporin maintained reductions in UPCR vs. control over the 3-yr treatment period in pts with #lupus nephritis #ACR22 @RheumNow ABST#1653 https://t.co/C4n6Yb8bdC

Venuturupalli et al. Elevated CASPASE 1 expression in synovial biopsies of inter-critical gout suggest ongoing NLRP3 inflammasome activity between gout attacks. @RheumNow #ACR22 Abstr#1808 https://t.co/OnJOpkRqH9 https://t.co/TGd6pn8Lne

• Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affecte…

"FRAX should be done even if DXA T-2.5 score as it will tell you the probability of fracture in the next 10 years" - Dr. M Humphrey Dr. B Humphrey #ACR22 #Osteoporosis Guidelines Session @rheumnow

Adami et al. GCs as low as 2.5mg/day assoc bone loss in RMD. Preventable with anti-resporptives. GC>=5mg/day aHR 2.37 for fracture @RheumNow #ACR22 Abstr#L01 https://t.co/1Q8dDarcAB https://t.co/dW4glkerAL

• Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health …

Nair et al. HLA-B*5801 allele in African American gout patients. Present in 8%. Higher than expected, ?need for screening pre-allopurinol? @RheumNow #ACR22 Abstr#1793 https://t.co/KrsjQ836BY https://t.co/bmPyqQi7OF

• Prevalence of HLA B*5801 Allele Among African American Patients with Gout in an…

#ACR22 #Osteoporosis Guidelines Case Example: The FRAX score needs to be adjusted (multiply by 1.15 or 1.2) in pts who are expected to have cumulative dose >5 grams/year of steroids @rheumnow https://t.co/wF8LP0iZjw

Steroid-sparing in PMR: methotrexate most used, but what is the evidence? Christian Dejaco says: variable at best. We need a proper RCT - and it’s on its way. @Sarah_L_Mackie @profbdasgupta @DrMaxYates1 @CatherineL_Hill @drceowen #ACR22 @RheumNow https://t.co/dxaPdVcOPQ

Across extended MACE endpoints risk was numerically higher with tofacitinib vs TNFi in pts with a history of artherosclerotic CV disease (ASCVD). CV risk (MACE-8 with HF +VTE) was higher in the Tofa 10mg bd vs TNFi. Buch M #L06 https://t.co/lFXl2ywbZe #ACR22 @RheumNow

• Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib …

Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcomes sustained. No joint difference to ADA, skin slightly better @RheumNow #ACR22 Abstr#L02 https://t.co/RjCV8Hb3HR https://t.co/a0NQFyFZlt

• Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Ar…